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Skin wounds are a prevalent problem for the equine industry, both for the well-
being of the animals and the financial impact of treatment. Chronic wounds often arise 
in horses, and this is thought to be due to poor vascularisation, sustained inflammation 
and high tissue tension preventing the wound from closing efficiently. Chronic wounds 
can take months to heal and can increase the risk of secondary infections.  
Previous research has identified two Orf virus proteins, VEGF-E and viral 
(v)IL-10, which decreased the immune response and improved healing in murine 
models of burn and traumatic wounds. Orf virus IL-10 is an anti-inflammatory cytokine 
that reduces inflammatory signalling and macrophage infiltration, thereby reducing 
fibrosis and scarring. VEGF-E is a vascular endothelial growth factor that promotes 
wound re-epithelialisation, re-vascularisation and closure. As these proteins work 
across a range of species, it was hypothesised that similar effects would be seen if these 
proteins were administered to chronic wounds in horses. The aims of this research 
project were to assess if the two viral proteins’ functions extended to equine cells and 
tissues.  
An equine cell line was generated by culturing cells from a thoroughbred horse 
skin biopsy. Cell proliferation and migration in the presence of the viral proteins was 
examined using a wound scratch assay. No changes in closure rate were observed after 
incubation with either protein. RNA expression in response to the viral proteins in the 
presence and absence of inflammatory stimuli was examined using quantitative PCR. 
Changes in inflammatory and fibrosis gene expression were observed in response to 
vIL-10. 
Biopsies from chronic equine wounds, with or without VEGF-E and vIL-10 
treatment, were analysed for regulatory and histological changes. Quantitative PCR 
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analysis of wound biopsies taken after 2, 7 and 14 days, and after final wound closure, 
showed an immediate reduction in some inflammatory and fibrotic mediators in treated 
wounds. Histological analysis showed a temporary increase in the thickness and length 
of the regenerating epidermis in treated skin. Immunohistochemical analysis of wound 
sections showed increased angiogenesis in the newly forming granulation tissue in 
treated skin, and a reduction in the infiltration of innate immune cells. 
These findings suggest that the viral proteins are active on equine cells but that 
the dosage and timing for treatments with VEGF-E and vIL-10 require optimisation to 
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1 Introduction 
1.1 Structure of skin 
Skin is the outermost barrier for the body, which protects the internal organs 
from external insults and water loss. It is a highly regenerative, complex tissue that is 
made up of two main layers; the outer epidermis and the underlying dermis. The 
epidermis consists of a stratified epithelium made up of approximately 95% 
keratinocytes (Lai-Cheong and McGrath, 2009). The basal keratinocytes are highly 
proliferative and produce daughter cells, which differentiate through the five layers of 
the epidermis: the strata basale, spinous, granular, lucid (found only in thick areas such 
as soles of feet and palms of hands) and the outermost stratum corneum. (Lai-Cheong 
and McGrath, 2009; Wickett and Visscher, 2006). The stratum corneum is highly 
stratified and the keratinocytes in this layer undergo nuclear digestion and envelope 
cross-linking to differentiate into corneocytes. They are constantly shed to protect the 
skin from absorption of chemicals and infection by pathogens. The other 5% of cells in 
the epidermis are the melanocytes which provide the skin with pigment, Merkel cells 
which transmit sensory information, and Langerhan cells (dendritic immune cells) 
which clear pathogens by phagocytosis (Lai-Cheong and McGrath, 2009). 
 The epidermis is separated from the underlying dermis via a thin basement 
membrane, consisting of less than 200 nm of closely intertwined proteins which link 
the basal keratinocytes to the fibres of collagen within the dermis (Lai-Cheong and 
McGrath, 2009). The underlying dermal layer is subdivided into two parts: the papillary 
dermis and reticular dermis. The papillary dermis is in contact with the basement 
membrane and contains blood vessels and sensory nerve endings. The reticular dermis 
sits deeper than the papillary dermis and functions to attach the entire dermis to the 
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subcutis layer (Lai-Cheong and McGrath, 2009). The dermis is also rich with 
connective tissue, and the cells that produce this matrix, fibroblasts. The dermis also 
contains mast cells and specialised macrophages to aid in immune control and 
clearance of unwanted debris (Yung, 2014). Other skin components, such as hair 
follicles and glands, are rooted in the dermal layer and project up through the epidermis 
(Martin, 1997). 
1.2 Stages of wound healing 
When skin is wounded, a series of events occur to allow the skin to regenerate 
and heal over time. These can be divided into three major stages: inflammation, repair 
and remodelling (Gurtner et al., 2008). Inflammation is the first stage of wound healing 
and is characterised by haemostasis, which stops bleeding, followed by an infiltration 
of immune cells into the wound bed. Haemostasis is induced by platelet aggregation 
and clotting factors to form a fibrin clot. This clot plugs the damaged blood vessels and 
creates a matrix onto which the incoming inflammatory cells and growth factors can 
attach.  
The neutrophils and macrophages play an important role in initial wound 
healing and arrive sequentially after wounding. They enter the surrounding tissues 
through damaged blood vessels, and are attracted to the site of injury by chemokines, 
such as momcyte chemotactic protein (MCP-1) and macrophage inflammatory protein 
(MIP-2α) produced by activated immune cells that are already present in the injured 
tissue (Shaw and Martin, 2009). Neutrophil invasion generally clears after a few days, 
while macrophages continue to accumulate to assist in wound healing (Martin, 1997).  
These immune cells are important in the onset of fibrosis and the debridement of the 
wound (Leibovich and Ross, 1975; Wynn and Barron, 2010).  
!
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Aggregated platelets and activated innate immune cells produce growth factors 
such as vascular endothelial growth factor (VEGF), platelet-derived growth factor 
(PDGF), epidermal growth factor (EGF) and transforming growth factor (TGFβ). These 
growth factors play an important part in immediate wound healing by encouraging 
epithelial cell migration, upregulation of fibrotic genes in fibroblasts, and 
vascularisation (Barrientos et al., 2008; Martin, 1997).  
After haemostasis has been achieved and inflammatory cells have phagocytosed 
any foreign pathogens, the next step in wound repair is re-epithelialisation. At this 
point, activated macrophages produce cytokines such as interleukin (IL)-10 and 
transforming growth factor (TGFβ1), which dampen down the immune response and 
inhibit further inflammation (Wynn and Barron, 2010).  
Re-epithelialisation occurs two to ten days after the initial injury and during this 
phase, the basal keratinocytes in the epidermis migrate across the wounded space in 
response to stimuli such as EGF and VEGF (Barrientos et al., 2008). In order to do this, 
keratinocytes need to free themselves from the basal membrane by dissolving 
hemidesmosome integrin attachments from the basal laminin. The keratinocytes closest 
to the wound edge then express new integrins that allow them to migrate along the 
basal lamina. In order to migrate through the fibrin clot, these cells must express 
plasmin and matrix metalloproteinases (MMPs) to dissolve the fibrin and collagen 
network (Martin, 1997). The integrin expression is restored to allow the basal 
keratinocytes to cease migration and anchor to the basement membrane.  
Fibroblasts migrate into the lower wound space from the dermis and lay down a 
disorganised matrix of collagen (Gurtner et al., 2008). The underlying connective tissue 
laid down by fibroblasts begins to contract to bring the wound margins in closer and aid 
the rate of re-epithelialisation. This contraction is largely due to the activity of 
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myofibroblasts, a specialised differentiation of fibroblasts with contractile muscle actin 
(Gurtner et al., 2008). The new collagen matrix aids vascularisation, which aims to 
supply the new tissue with an adequate blood circulation (Gurtner et al., 2008). An 
important growth factor that contributes to the formation of new blood vessels during 
tissue repair is vascular endothelial growth factor (VEGF)-A (Galiano et al., 2004; 
Gurtner et al., 2008; Johnson and Wilgus, 2014). This class of growth factors act 
through the specific receptors VEGF Receptor (VEGFR)-1, VEGFR-2 and VEGFR-3 
(Johnson and Wilgus, 2014). VEGF-A only binds to VEGFR-1 and VEGFR-2 (Holmes 
et al., 2007). VEGFR-2 has been shown to promote cellular migration and proliferation, 
and is mostly expressed on vascular endothelial cells to increase vascularisation 
(Holmes et al., 2007). VEGFR-1 has a higher affinity for VEGF-A than VEGFR-2, and 
is expressed on vascular endothelial cells. This receptor is also expressed on 
macrophages to promote inflammation and has been implicated in inflammatory 
diseases (Shibuya, 2006). VEGF-A can act through both receptors to increase 
angiogenesis and inflammation during the repair stage of wound healing (Johnson and 
Wilgus, 2014). 
The final step of wound healing is resolution, which is important in restoring 
functionality to the skin and preventing scarring. Once the keratinocytes have migrated 
across the entire surface of the wound they restore hemidesmosome attachments and 
differentiate to regenerate the stratified epithelium (Shaw and Martin, 2009). If the 
wound penetrates into the dermis, sweat glands and hair follicles may be destroyed. 
The regenerating skin cells are unable to create new hair or sweat glands and hence the 
resolved wound would lack these appendages (Martin, 1997). 
New blood vessels form rapidly during angiogenesis and undergo maturation to 
create a refined and functional vascular network (Shaw and Martin, 2009). In the 
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dermal scar, MMPs such as collagenase-1 are produced to degrade the collagen III 
matrix and slowly replace it with collagen I. This remodelling helps to strengthen the 
new tissue to prevent further damage and restore the protective function of the skin. 
During this resolution stage there is programmed cell death of many of the contractile 
myofibroblasts, endothelial cells and macrophages, which leaves an acellular scar 
(Gurtner et al., 2008).  
1.3 Pathologies associated with wound healing 
The process of wound healing is usually a tightly controlled process that 
successfully restores the skin’s protective function. However, this process is not always 
a flawless mechanism, and can often fail to heal correctly in individuals with 
underlying health concerns or those with genetic abnormalities (Sen et al., 2009). 
Incorrect healing can lead to numerous pathologies, the extremes of which are chronic 
wounds or fibroproliferative scars.  
Chronic wounds are persistent, non-healing wounds, which fail to close in a 
timely fashion and pose a high risk for secondary infections. Chronic wounds often 
feature prolonged inflammation and a reduction in epithelial regeneration (Demidova-
Rice et al., 2012). A main subset of human chronic wounds is vascular ulcers, which 
can be a result of limited blood supply due to arterial blockages (arterial ulcers) or a 
rise in venous pressure causing a back-flow of venous blood (venous ulcers). Both 
forms of chronic wounds, along with wounds associated with diabetes or neuropathies, 
fail to heal and as a result they are able to develop secondary infections that pose a 
serious risk of blood-borne disease to the patient (Demidova-Rice et al., 2012).  
In humans, fibroproliferative scars are called keloids which are the result of 
fibroblasts laying down too much fibrin and collagen rapidly, preventing the growth of 
epithelial cells. This over-activity of fibroblasts is uncommon across most mammalian 
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species and is almost completely limited to humans and horses (Ud-Din et al., 2014).  
The predisposition to form keloids in humans has been linked to differences in gene 
expression between normal fibroblasts and those isolated from keloid scars (Russell et 
al., 2010).  
Wound healing pathologies are significant due to the large impact they have on 
the health system and economy. Wound pathologies are fairly common, as they can 
arise from a variety of causes and affect more than 6 million patients a year in the 
United States alone (Sen et al., 2009). The economic burden of wounds is rising every 
year due to an increase in other health-related issues such as diabetes and obesity. As a 
result the current market cannot provide adequate treatments to keep up with the 
demand (Sen et al., 2009).  
1.4 Biological wound therapies 
Biological therapies by definition are a broad range of therapies that target 
wound healing by promoting stimulation of the body’s own healing responses 
(Braddock et al., 1999; Rennert et al., 2013). Such therapies are designed to target 
processes that are altered in certain diseased states in order to restore effective wound 
healing. Today there are many products that aid in the resolution of chronic wounds, 
including biological skin equivalents, growth factors and stem cell therapies (Braddock 
et al., 1999; Brown et al., 1989; Rennert et al., 2013).  
Chronic wounds are thought to be caused by a dysregulation of endogenous 
growth factors. An increasing area of interest for biological wound therapies involves 
the application of exogenous growth factors (Rennert et al., 2013). Many growth 
factors, such as PDGF, TGFβ1, EGF and VEGF-A have previously been shown to 
improve the rate of wound repair in chronic wounds (Beck et al., 1991; Brown et al., 
1989; Heldin and Westermark, 1999; Nall et al., 1996). 
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Biological skin equivalents are also highly common forms of treatment for 
chronic wounds, and these are composed of a complex of cells and matrix proteins that 
are placed over the wound area to promote wound re-epithelisation and repair (Rennert 
et al., 2013). 
Keloid scars require a different approach for therapies than chronic wounds as 
they result from over proliferation. The underlying cause of keloid scars is somewhat 
unclear, but there is a lot of research into potential treatments (Viera et al., 2010). 
Growth factors are also important for treatments against hypertrophic scars. Hepatocyte 
growth factor (HGF) is involved in angiogenesis, which increases the blood supply to 
the granulation tissue of the wound. This growth factor also alters levels of cytokines 
such as TGFβ1, which have been implicated in the formation of hypertrophic scars 
(Ono et al., 2004). Basic fibroblast growth factor (FGF-2) helps inhibit the production 
of excess collagen in fibrosis and assists in increasing the rate of wound closure (Ono et 
al., 2007). While these growth factors aid in reducing the production of hypertrophic 
scars, other treatments can also contribute to the process. Treatments include 
neutralising antibodies or small interfering RNAs against growth factors such as TGFs, 
which are involved in cell proliferation and collagen production. As mentioned above, 
other growth factors like HGF are also used to target the detrimental effects of these 
growth factors (Viera et al., 2010).  
1.5 Wound healing processes and treatments in horses 
Problematic wounds in humans are challenging to understand and appropriate 
animal models would help to gain a better idea of the underlying problems in aberrant 
wound healing processes. The solution may lie in veterinary medicine, as a number of 
human complications are found in companion animals such as horses (Theoret and 
Wilmink, 2013; Volk and Bohling, 2013). 
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Horses are prone to developing traumatic injuries in the limb due to their 
tendency to flee during the fight or flight response. These wounds usually result in 
large areas of tissue loss and as a result are left to heal by second intention (left open to 
heal with no suturing), which can often take a long time to heal (Theoret and Wilmink, 
2013). While body wounds usually heal with no detrimental effects after 4 weeks, limb 
wounds often take 10 to 12 weeks to heal. This can lead to the development of chronic 
wounds or excessive fibrosis.  
Horses, like humans, develop chronic wounds that fail to close and pose risks 
for further infection (Westgate et al., 2010). The tendency to form chronic wounds is 
thought to stem from the high tissue tension in limbs, as well as a poor vascular supply 
and constant contamination of the wound (Westgate et al., 2010). Studies have shown 
that contraction is a key mediator in second intention wound healing, which is 
controlled by differentiated myofibroblasts that contain actin filaments (Wilmink and 
van Weeren, 2004). The myofibroblasts in horses are less organised compared to pony 
wounds, which results in a slower rate of contraction (Wilmink et al., 1999b). 
Epithelialisation of horse limb wounds starts much later in the wound healing time 
course (after 4 weeks compared to 3 weeks in muscle wounds). This delayed 
epithelialisation and lack of wound contraction aid in the formation of chronic wounds 
(Wilmink et al., 1999a). The inflammatory response in horses has also shown to be 
implicated in the slow rate of healing of limb wounds (van den Boom et al., 2002; 
Wilmink et al., 1999b). Inflammatory cells reside in limb wounds longer than in body 
wounds, and an extended inflammatory response may be preventing the onset of 
fibrosis to allow the wound to heal (Wilmink et al., 1999b). Fibrin deposits in the limb 
wounds fail to clear effectively after the initial inflammation stage, which can hinder 
re-epithelialisation. This is another indication that the inflammatory response is 
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dysregulated in limb wounds of horses, causing the formation of chronic, non–healing 
wounds.   
Horses can also develop fibrotic wounds called exuberant granulation tissue 
(EGT), not unlike keloid scars in humans (Theoret and Wilmink, 2013).  It has been 
reported that horses also have a genetic predisposition to forming EGT which contain a 
unique subset of fibroblasts (Theoret et al., 2013). The process of bandaging the limbs 
may extrapolate the formation of EGT, or “proud flesh”. These EGT scars are 
detrimental to limb function and are susceptible to re-injury. The etiology and 
formation of these scars are very similar in humans and horses, the only difference 
being that EGT is not epithelialised (Theoret and Wilmink, 2013). EGT formation is 
due to an excessive rate of fibrosis that grows over the margins of the wound area. 
TGFβ1 has been implicated in the formation of EGT in the limbs of horses. Levels of 
TGFβ1 are elevated in limb wounds compared to body wounds and this pro-fibrotic 
cytokine can increase the production of collagens to promote the onset of EGT (Theoret 
et al., 2001; van den Boom et al., 2002). EGT is often characterised by an increase in 
the production of new blood vessels (angiogenesis) (Dubuc et al., 2006; Lepault et al., 
2005). However, these vessels are often occluded and so lack the capacity to supply 
blood to the tissue. This generates a hypoxic environment that promotes the excessive 
production of extracellular matrix, resulting in formation of EGT.  
Many studies have looked at the effects of human therapies on equine wounds, 
such as topical treatments and debridement and several studies have investigated genes 
involved in the production of exuberant granulation tissue in an attempt to identify a 
therapeutic target (Berry and Sullins, 2003; Sherman et al., 2007). Topical treatments 
are commonly used in both human and animal practice and involve applying a 
substance to the wound followed by bandaging/strapping the wound to prevent the 
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treatment from shifting. The downside to this sort of treatment is the requirement of 
bandaging, which as mentioned above has been shown to encourage the development 
of EGT (Theoret et al., 2002). Treating these equine wounds is challenging, as horses 
are highly active and limb immobilisation is not possible.  
A common type of equine wound therapy is the application of antimicrobial 
compounds such as povidine (iodine) ointment, manuka honey, bacitracin or silver 
sulfadiazine (Berry and Sullins, 2003; Bischofberger et al., 2011; Engelen et al., 2004). 
Antimicrobials are thought to aid in wound healing by clearing infection, as this 
bacterial colonisation has been implicated as a cause of chronic wounds (Westgate et 
al., 2010). These topical treatments are able to prevent secondary infections from 
occurring, but used alone they fail to improve the rate of wound closure (Berry and 
Sullins, 2003; Bischofberger et al., 2011). 
As well as antimicrobial therapies, many studies have looked at the effect of 
alternative human therapies such as maggot debridement, topical oxygen therapy and 
stem cell therapies (Bussche et al., 2015; Sherman et al., 2007; Theoret, 2009; Tracey 
et al., 2014). This class of treatments aim to improve the wound microenvironment to 
allow optimal healing. However, they are often difficult to administer and require 
multiple treatment sessions, which puts physical and financial strain on owners. 
The use of biological therapies has been well-researched in human wounds, and 
involves the addition of biological factors such as connective tissue components or 
growth factors to the wound site. Some examples of biological therapies studied in 
horses include ketanserin, bovine collagen and activated protein C (Bello, 2002; 
Bischofberger et al., 2015; Engelen et al., 2004). These treatments aim to target 
components of wound healing that have been shown to be altered in pathologies such as 
chronic wounds or EGT, such as irregular inflammation and fibrosis. Biological 
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therapies reduce the requirement for surgeries or bandaging, to reduce time, money and 
stress on the animal.  
Cytokines and growth factors are also being investigated for the treatment of 
both chronic and fibrotic wounds in humans, yet very little research has been 
undertaken in horses. It is likely that new protein therapies can be developed to target 
the healing impairments associated with equine wounds. Evaluation of these protein 
therapies in equine wounds would also provide valuable information regarding their 
potential use in similar human conditions.  
1.6 Orf virus and wound healing 
Orf virus (OV) is part of the parapoxvirus genus and has the ability to cause 
pustular and exanthemous lesions in sheep, goats and humans. OV infection initiates in 
wounded skin and lesions formed by the virus are highly vascularised and proliferative. 
However, these lesions heal successfully with limited scarring. Investigation into the 
genome of the virus identified a set of host manipulating factors, of which two proteins 
were identified as a potential cause of the successful resolution: vascular endothelial 
growth factor (VEGF)-E, a homolog of human VEGF, and OV interleukin-10 (vIL-10), 
an anti-inflammatory cytokine. The cellular homologs of these factors (VEGF-A and 
IL-10) are key mediators in the regulation and maintenance of the wound healing 
response. Viral versions of these genes have demonstrated enhanced wound healing 
capabilities in smaller mammals such as mice (Fleming et al., 2015; Mercer et al., 
2006; Wise et al., 2012; Wise et al., 2014).  
As described previously in this report, cellular VEGF-A aids in the deposition 
of the fibrin matrix and induces blood vessel and epidermal regeneration, which it 
performs through the interaction with VEGFR2 (Johnson and Wilgus, 2014; Wise et 
al., 2012). VEGF-A also binds to VEGFR1 and this activity can lead to sustained 
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vascular leakage and tissue inflammation. VEGF-E binds solely to VEGFR2 and due to 
this specific interaction it does not have the adverse inflammatory effects caused by 
VEGF-A (Wise et al., 1999). The VEGF-E homolog was shown to induce 
vascularisation in mice, as well as an increase in epidermal thickness and wound re-
epithelialisation (Wise et al., 2012). The activation of keratinocytes and endothelial 
cells without the increased inflammation allows VEGF-E to improve wound closure 
and resolution, making this an ideal candidate for treatment of chronic wounds in 
horses. 
OV produces a second protein, vIL-10, which helps wound resolution (Wise et 
al., 2014). Mammalian IL-10 is an anti-inflammatory cytokine that helps to limit 
inflammation by preventing the infiltration of macrophages and neutrophils to the 
wound site (Sato et al., 1999). It has also been implicated in control of scar tissue 
formation. This viral homolog of IL-10 was shown to exhibit similar effects in that it 
limited macrophage infiltration and reduced the expression of key inflammatory genes. 
It also accelerated wound re-epithelialisation and reduced fibrosis and scar tissue 
formation (Wise et al., 2014).  
Combining the viral VEGF-E with the viral IL-10 demonstrated a greater 
improvement in wound healing, and further reduced inflammation and fibrosis 
(unpublished data). These observations were not seen in wounds treated with the 
equivalent cellular combination (VEGF-A and IL-10). The viral proteins have been 
shown to be active across a range of species, including ovine, murine, human, bovine 
and ovine (Wise et al., 2007; Wise et al., 2012; Wise et al., 2014; Wise et al., 2003; 
Wise et al., 1999), and there is a high level of homology between the protein receptors 
across these species (84 – 98% for VEGF-E, 53 – 93% for vIL-10), hence it is likely 
that the proteins will also be active in equine species.  
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1.7 Hypothesis and aims 
The specific activities of VEGF-E and viral IL-10 led to the hypothesis that a 
combination treatment will promote closure and limit EGT formation in equine limb 
wounds. Specifically, the proteins will achieve this by promoting wound re-
epithelialisation and re-vascularisation while limiting inflammation and fibrosis in 
equine wounds. The aim of this project is to determine if the viral proteins are 
biologically active in equine cells and tissues. This aim will be approached by two 
studies; in vitro in an equine cell line to determine if the proteins are active in these 
cells and in vivo in chronic wounds of thoroughbred horses to determine if the proteins 





2 Materials and Methods 
2.1 Protein methods 
2.1.1 Protein production 
HEK293-EBNA cells transfected with a plasmid encoding FLAG-tagged 
versions of the VEGF-E or vIL-10 genes were used for protein production (Imlach et 
al., 2002; Wise et al., 2003). The cells were grown in Dulbecco's Modified Eagle's 
Medium (DMEM) containing 10% heat-inactivated fetal calf serum (FCS), 50 ng/mL 
gentamicin, 2 unit/mL penicillin, 1 µg/mL streptomycin and 0.2 µg/mL kanamycin 
(PSK) and 20 mg/mL hygromycin B (Sigma). Cells were grown at 37 oC in 5% CO2 
until confluent, then the supernatant was collected, clarified by centrifugation at 1,200 
rpm for 5 min, then stored at -80 °C. 
2.1.2 Protein purification and concentration 
Supernatant containing FLAG-tagged protein was transferred to 200 mL 
disposable centrifugation tubes with 200 µL of M2 anti-FLAG agarose beads (Sigma). 
Tubes were rotated overnight at 4 °C then beads were separated from the supernatant 
using a chromatography column. The beads were then washed three times with 10 mL 
tris-buffered saline containing 0.02% Tween-20 (TBS-T). FLAG peptide (Sigma) was 
then added to the column at a concentration of 100 µg in 5 mL volume of TBS-T and 
the eluted protein was collected. The thawed protein was concentrated, and residual 
FLAG peptide removed using a filtered centrifuge tube (Amicon Ultra15, 15kDa pore 
size) spun at 5,000 rpm for 30 min at 4 °C. The protein was then buffer exchanged by 
the addition of 5 mL filter-sterilised phosphate-buffered saline (PBS), which was 
reduced to a final volume of 500 µL by centrifugation as described above. The final 
protein stock was distributed into aliquots and stored at -80 °C. 
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2.1.3 Protein concentration and quantification 
Protein samples were diluted 1:1 with reducing sample buffer then boiled for 5 
min. Full-range rainbow marker (5 µL, Amersham, RPN800E), 3 µL, 8 µL and 20 µL 
of carbonic anhydrase (CA), purified VEGF-E and vIL-10 were loaded into wells. The 
proteins were resolved on a 10-15% stacked SDS-page gel run at 100 V for 2 hr. Gels 
were then stained overnight with Coomassie blue, destained in methanol and 
photographed using the BioRad ChemiDoc. Band densities were measured using 
ImageJ software and the readings for CA were used to generate a standard curve. 
Concentrations of purified VEGF-E and vIL-10 were calculated by taking the average 
of the three band densities and using the equation from the standard curve. 
2.2 Equine cell culture and characterisation 
2.2.1 Trypsin cell extraction 
Equine skin samples were obtained from a trial conducted at Massey University 
with Institutional approval (MUAEC 14/84). Cells were extracted from equine skin 
using a method adapted from Yamada (Yamada, 2003). Biopsies (four x 25 mm2) of 
equine skin from the thoracic (body) and metacarpal (limb) regions were sanitised by 
soaking in Betadine for three periods of 1 minute, followed by incubation in 0.25% 
trypsin overnight at 4 °C. The epidermis was then scraped from the dermis using sterile 
forceps and a scalpel, and each was then processed through a cell strainer to separate 
the cells. The body and limb cell suspensions were resuspended in 5 mL equine 
fibroblast growth media (eFGM): DMEM supplemented with 10% FCS, 50 ng/mL 
gentamicin, PSK (concentrations indicated in 2.1.1) and 29 µg/mL L-glutamine, or in 5 
mL equine keratinocyte growth media (eKGM): Eagle's Minimum Essential Medium 
(EMEM) supplemented with 10% FCS with Ca2+ chelated with 50 mg/mL Chelex 100 
Resin (Bio Rad, 1421253), 50 ng/mL gentamicin, PSK (concentrations indicated in 
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2.1.1) and 29 µg/mL L-glutamine. Cells were incubated in a 96-well plate at 37 °C in 
5% CO2 until colonies were obtained. Wells containing single colonies were harvested 
using 25 mg/mL trypsin, counted using trypan blue exclusion on a haemocytometer, 
and were maintained at a density of between 1 x 104 – 1 x 105 cells/mL. Once the 
fibroblast lines were created, aliquots of 1 x 107 cells were diluted in 1 mL 10% 
DMSO/80% DMEM/10% FCS and were placed in liquid nitrogen storage.  
2.2.2 Collagenase dispase cell extraction 
Cells were extracted from equine skin using Collagenase/Dispase digestion 
following the manufacturer’s instructions. Biopsies (four x 25 mm2) of body and limb 
equine skin were sanitised by soaking in Betadine for three periods of 1 minute and 
were incubated in 100 mg/mL Collagenase/Dispase (Roche) in PBS overnight at 4 °C. 
The skin was processed through a metal tea strainer to remove debris, followed by a 
cell strainer to separate the cells. The body and limb cell suspensions were resuspended 
in 5 mL eFGM or in 5 mL eKGM. Cells were incubated in a 96-well plate at 37 oC in 
5% CO2 until colonies were obtained. Wells containing single colonies were harvested 
using 25 mg/mL trypsin, counted using trypan blue exclusion on a haemocytometer, 
and were maintained at a density of between 1 x 104 – 1 x 105 cells/mL. Once the 
fibroblast lines were created, aliquots of 1 x 107 cells were diluted in 1 mL 10% 
DMSO/80% DMEM/10% FCS and were placed in liquid nitrogen storage.  
2.2.3 Explant cell extraction 
Cells were extracted from equine skin using a method that was adapted from 
Vangipuram et al. (Vangipuram et al., 2013). Tissue culture plates (6-well) were coated 
in filter-sterilised 0.1% gelatin in PBS for 30 min, after which the gelatin was removed. 
Biopsies (four x 25 mm2) of body and limb equine skin were dissected to 1 mm2 
explants and three were placed on the gelatin coating in each well. Following 7 day 
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incubation in 0.4 mL eFGM, explants were removed and the medium was replaced with 
either eFGM or eKGM. Wells containing large colonies were harvested using 25 
mg/mL trypsin, counted using trypan blue exclusion on a haemocytometer, and were 
maintained at a density of between 1 x 104 – 1 x 105 cells/mL. Once the fibroblast lines 
were created, aliquots of 1 x 107 cells were diluted in 1 mL 10% DMSO/80% 
DMEM/10% FCS then were placed in liquid nitrogen storage.  
2.2.4 Immunofluorescent analysis of equine fibroblasts 
Equine fibroblasts (5x105) were seeded into a 6-well plate containing sterilised 4 
cm2 coverslips and incubated in eFGM at 37 °C in 5% CO2 until confluent. Media was 
removed from the wells and cells were fixed overnight in 0.5% Zinc-Salts fixative. 
Cells were then equilibrated in TBS for 20 min and incubated with antibodies against 
vimentin (Vim, Cell Signaling Technology; 1:50 dilution) and α-smooth muscle actin 
(αSMA, Sigma-Aldrich; 1:400 dilution) in 20 µL of TBS containing 0.1% bovine 
serum albumin for 2 h at room temperature. For the final 30 min of the incubation, 20 
µL of 4’,6-diamidino-2-phenylindole (DAPI, 75 nM, Invitrogen) was added, followed 
by a TBS wash. Coverslips were mounted onto microscope slides using SlowFade Gold 
(7 µL, Invitrogen) and stored at 4 °C overnight. Stained cells were photographed at 40 
X magnification on the upright fluorescence microscope (Olympus BX-51) using 
cellSens Software (Olympus). Images were prepared on Adobe Photoshop. 
2.2.5 PCR analysis of fibroblast receptors 
Equine fibroblasts (3 x 106) were grown to confluence in a 75 cm2 tissue culture 
flask. Cells were washed with PBS and harvested using 0.25% trypsin, and pelleted by 
centrifugation at 1,200 rpm. Cells were then homogenised in lysis buffer (Qiagen) 
using a 1 mL syringe and a 20-gauge needle. RNA was isolated using the Geneaid 
TriRNA Pure Kit according to the manufacturer’s instructions. Quanta Biosciences’ 
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PerfeCta DNase I (RNase-free) was used following the manufacturer’s instructions to 
remove DNA contamination, and sample concentrations (ng/µL), 260/230 and 260/280 
ratios were determined with a spectrophotometer (NanoDrop). Synthesis of cDNA was 
carried out with SuperScript III First-Strand Synthesis SuperMix for qRT-PCR 
(Invitrogen) following the manufacturer’s instructions, using 500 ng RNA/rxn.  
A standard PCR reaction was carried out using the Expand High Fidelity PCR 
System (Roche) in a 50µL volume. Forward and reverse primers used to detect equine 
VEGFR1, VEGFR2 and IL-10Rα genes are listed in Appendix 1, Supplementary Table 
1. Each reaction mix contained 5% of the cDNA sample and 100 mM of each primer 
and underwent the following cycling protocol: denaturation at 94 °C for 15 sec, 
annealing at 60 °C for 30 sec and elongation at 72 °C for 45 seconds. The PCR 
products were analysed on a 1% agarose gel containing 500 ng/mL ethidium bromide. 
DNA ladder (3.5 µl of 1Kb Plus, Invitrogen) or 10 µl of PCR product was added to 
each well in loading dye. Gel electrophoresis was conducted in TAE buffer at 100V for 
1 h. Bands were visualised under UV light using Chemi-Doc XRS using the Quantity 
One software (Bio-Rad).  
2.3 Assays with equine fibroblasts 
2.3.1 Quantitative PCR analysis of gene expression 
Changes in gene expression in response to the proteins were assessed using 
quantitative PCR. Equine fibroblasts (3 x 106) were seeded in 75 cm2 tissue culture 
flasks and grown to confluence in 10 mL eFGM. Media was removed and cells were 
washed twice in PBS before the addition of 10 mL DMEM supplemented with 0.1% 
BSA, 50 ng/mL gentamicin, PSK (concentrations indicated in 2.1.1) and 29 µg/mL L-
glutamine (equine fibroblast assay medium, eFAM). To promote quiescence, cells were 
incubated in this basal media overnight at 37 °C in 5% CO2. Cells were washed in PBS 
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twice and 10 mL of eFAM containing 200 ng/mL VEGF-E or 20 ng/mL vIL-10 or 
media alone was added. An additional set of flasks were treated with the above and 50 
µg/mL polyinosinic:polycytidylic acid (PolyI:C) to induce an inflammatory response in 
the cells. The fibroblasts were incubated for 2 h then washed twice with PBS and 
harvested using 0.25% trypsin. eFGM was added to neutralise the trypsin and cells 
were spun down in a microcentrifuge at 1,200 rpm to form a pellet. Cells were 
homogenised and lysed to extract RNA, followed by cDNA synthesis as per section 
2.2.5. 
Quantitative PCRs were conducted using cDNA equivalent of 5ng RNA, the 
SYBR GreenER qPCR SuperMix (Invitrogen) and the Applied Biosystems 7500 Fast 
PCR machine, using primers in Appendix 1, Supplementary Table 1. Primer 
efficiencies were calculated and expression levels of genes were determined relative to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and to the levels in cells treated 
with media only. 
2.3.2 In vitro cellular migration assay 
Equine fibroblasts (1.25 x 105) were seeded into a 24-well plate and grown to 
confluence in eFGM.  Wells with confluent monolayers of cells were scratched down 
the centre of the well with a 200 µL pipette tip following a protocol adapted from 
Hulkower (Hulkower and Herber, 2011). Media and damaged cells were removed, and 
wells were washed twice with PBS. In initial assays, the media was replaced with 1 mL 
of eFAM containing 0-2% FCS or 0.1% BSA. In subsequent assays, the media was 
replaced with 1mL of either 200 ng/mL VEGF-E or 20 ng/mL vIL-10 in eFAM 
containing 0.1% BSA, or with media alone. Three replicate images were taken at the 
centre of each scratch at 0, 6, 12, 24 and 48 hours at 20 X magnification using the 
Olympus TH4-200 inverted microscope and the cellSens Software. In each image the 
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scratch area was measured using ImageJ. Changes in the scratch area were calculated as 
ratio of the original area at time = 0 h using the following equation: 
!"#$%!!"!!"#$#%&'!!"#$%"ℎ!!"!!"#$%&' = !"#$%"ℎ!!"#!!!"!!"#$!(!)!"#$#%&'!!"#$%"ℎ!!"#!!(! = 0) !
2.4 Equine skin methods 
2.4.1 Equine wound trial 
A trial was undertaken in thoroughbred horses to assess the effects of viral 
treatment in equine skin wounds. The trial was conducted at Massey University by 
Christine Theoret, Chris Riley and Christa Bodaan, with Institutional approval 
(MUAEC 14/84). Four horses were assigned to the chronic wound group. These horses 
were sedated with detomidine hydrochloride (0.01 mg/kg; intravenous (IV)) and 
butorphanol tartrate (0.04 mg/kg; IV). Hair was clipped from the dorso-lateral surface 
of both metacarpal areas and both thoracic walls in each horse. Local anesthesia was 
performed using 2% lidocaine hydrochloride. Four 2 cm x 2 cm (4cm2) areas on the 
dorso-lateral surface of each metacarpal area beginning just above the 
metacarpophalangeal joint, and on each lateral thoracic wall, 1.5 cm apart in a 
staggered vertical column were traced out and excised using a scalpel. These wounds 
were left to heal by second intention, and were bandaged postoperatively for 24 hours 
to control hemorrhage. After 24 hours, bandages were removed and viral therapy was 
administered to four wounds of one randomly assigned metacarpal area and one 
thoracic area.  
The viral therapy was extrapolated from previous mice experiments (Wise et 
al., 2012; Wise et al., 2014) so that vIL-10 and VEGF-E (1 µg and 10 µg of each 
respectively, in 200 mL PBS) were administered by subcutaneous injection adjacent to 
each border of each treated wound at 24, 48 and 72 hours. Full-thickness wound margin 
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samples were collected with an 8 mm diameter biopsy punch from one wound per site 
(body; limb; control; treated) at the time of wounding and after 48 hours, 7 days, 14 
days, and at final wound closure. These biopsies were halved at right angles to the 
junction between the wound and the intact skin border. One half of each samples was 
incubated in RNAlater stabilisation solution (Invitrogen) for 24 h prior to being snap 
frozen in liquid nitrogen and stored at -80°C for later RNA isolation. The other half of 
each biopsy was fixed in neutral-buffered 10% formalin for 7 days, then stored in 70% 
ethanol until being processed in paraffin. All frozen and paraffin-embedded skin 
samples were then shipped to the University of Otago for analysis. 
2.4.2 Quantitative PCR analysis of gene expression in equine skin 
Individual skin samples were placed into a mortar and pestle with liquid 
nitrogen and ground into a fine powder, transferred into a 2 mL microfuge tube with 
300 µL lysis buffer and homogenised with a 1 mL syringe and a 20-gauge needle. 1 mL 
Trizol (ThermoFisher) was added and mixed, then left to sit for 10 min. Chloroform 
(400 µL) was then added and mixed vigourously for 20 sec. The sample was left for 3 
min then centrifuged at 13000 rpm at 4 °C for 20 min. Supernatant was removed and 
incubated at 56 °C for 10 min with 2 ng proteinase K. RNA was extracted following the 
protocol outlined by the Geneaid TriRNA Pure Kit, including an on column 15 min 
incubation with RNAse-free DNase I at room temperature. Any remaining DNA 
contamination was removed using Quanta Biosciences’ PerfeCta DNase I (RNase-free) 
following the manufacturer’s instructions. Synthesis of cDNA was conducted as 
described in section 2.2.5. 
Quantitative PCRs were conducted using cDNA equivalent of 5ng RNA, the 
SYBR GreenER qPCR SuperMix (Invitrogen) and the Applied Biosystems 7500 Fast 
PCR machine, using primers in Appendix 1, Supplementary Table 1. Primer 
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efficiencies were determined and expression levels of genes were determined relative to 
GAPDH and to the levels in equine skin prior to wounding. 
2.4.3 Histological analysis of equine skin wounds 
Paraffin-embedded equine skin biopsies were trimmed of excess paraffin then 
cut into 4 μm sections using a microtome (Leica RM2025). The sections were mounted 
on DAKO slides for immunohistochemistry or Histobond slides (Marienfeld) for 
histological stains, and dried at 37 °C overnight.  
Paraffin-embedded sections were deparaffinised by washes in Xylene, and 
rehydrated by sequential washes in 100%, 95% and 70% ethanol then into water. The 
sections were stained for 2 min with Celestin blue and Haemotoxylin, washed in Scott’s 
water and rinsed in 95% ethanol. Next the sections were stained for 5 min with 0.5% 
Martius Yellow in 95% ethanol, washed in water, stained for 10 min in 1% Crystal 
Scarlet in 2.5% acetic acid, washed again in water then treated with 1% 
phosphotungstic acid for 2 min. After a water wash, sections were counterstained for 2 
min in Methyl Blue solution diluted 1 in 10 in 1% acetic acid, then rinsed in 1% acetic 
acid. The sections were dehydrated in 100% ethanol followed by a Xylene wash. 
Coverslips were mounted over the stained sections, sealed with clear nail polish and 
allowed to dry. The Histology Services Unit in the Pathology Department of the 
University of Otago performed the staining process. Photographs of the stained sections 
were taken at 4 X magnification using the upright microscope (Olympus BX-51) and 
cellSens software. Panoramics were generated using Adobe Photoshop. 
Changes in epidermal repair were analysed in each section using Image J. The 
length of the neo-epidermis was measured on the boundary with the dermis from the 
edge of the normal skin into the wound tissue. The thickness of the neo-epidermis was 
calculated as the mean of five measurements equally spanning the length of new 
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epidermis. The length of each rete ridge (epidermal projection entering the dermis) was 
measured and the sum of all rete ridge lengths for each section was calculated. 
2.4.4 Immunofluorescent analysis of equine skin wounds 
Paraffin sections were dehydrated by incubation overnight at 37 °C. They were 
deparaffinised in Xylene for 15 min, and rehydrated by sequential washes in 100% 
ethanol, 100% propan-1-ol, 90% propan-1-ol, and 70% propan-1-ol. Slides were then 
washed in 0.85% NaCl solution and re-equilibriated in PBS for 30 min. At this point, 
antigen retrieval methods varied for each antibody. Sections that were to be used with 
antibodies against α-smooth muscle actin (αSMA) or von-Willebrand factor (vWF) 
were placed in TBS pH 7.4 at 37 °C for 20 min. Sections that were to be used with 
antibodies against major histocompatibility complex (MHC-II) were incubated in 10 
mM sodium citrate pH 6 at 95 °C for 20 min using a decloaking chamber (Biocare). All 
sections were placed in room temperature TBS for 20 min prior to staining. Sections 
were incubated with the primary antibodies at the appropriate dilution, at the specified 
temperature in a dark, humid chamber, for the specified time, as listed in table 1. Where 
necessary this was followed by incubation with a secondary antibody following the 
conditions listed in table 1. For the final 30 min of the incubation, 80 µL of DAPI (75 
nM) was added. The sections were then rinsed in TBS and mounted in 10 µL SlowFade 
Gold before placement of the coverslips on microscope slides and storage at 4°C 
overnight. Stained sections were photographed at 4 X or 10 X magnification using the 
upright Olympus BX-51 fluorescence microscope using the cellSens Software. 
Panoramics were generated of each section using Adobe Photoshop.  
For sections incubated with antibodies against vWF and αSMA, the area of 
positive staining within the newly formed granulation tissue (wound dermis) was 
calculated as a percentage of the total granulation tissue area on ImageJ. The 
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percentage area that was stained positive for MHC-II was calculated as a proportion of 
the total section area (normal and wound tissue).  
 
Table 1. Antibody dilutions, incubation times and clone identification. 
Antibody (Clone)# Dilution 
(80 µL volume)#
Incubation Time# Company (Cat. No.)#
Primary# ! ! !
Mouse α-αSMA-Cy3 (1A4) 1:400# 2 hours RT# SigmaVAldrich!C6198!
Rabbit α-human vWF 
(polyclonal)  
1:200# 2 hours RT # DakoCytomation!A!0082!
Mouse α–equine MHC-II 
(CVS20) 
1:50# Overnight 4°C# Abcam!ab23206!
Rabbit α -Vimentin-Alexa 
Fluor488 (D21H3) 
1:50# 2 hours RT# Cell!Signalling!9854!
Secondary ! ! !
Goat α-rabbit 488  1:500# 1 hour RT# Invitrogen!AV11034!
Goat α-mouse 488 1:500# 1 hour RT# Invitrogen!AV110001!
 
2.5 Statistical analysis 
Statistical analysis of the data obtained from treated and untreated equine skin 
wounds at individual time points were performed using a paired T-test when matching 
samples from each horse were available, and using an unpaired T-test when matching 
samples were unable to be generated. Normal distribution could not be determined 





3.1 In vitro analysis of viral protein activity in equine cells 
The initial objective of this project was to determine the effects of the viral 
proteins on equine cells. The first step was therefore to produce the recombinant viral 
proteins, VEGF-E and vIL-10, for use in bioassays. An equine fibroblast cell line was 
then generated from skin biopsies taken from the thoracic (body) and metacarpal (limb) 
regions of thoroughbred horses for use in bioassays. As the viral proteins have both 
been shown to regulate inflammation and fibrosis (Wise et al., 2012; Wise et al., 2014), 
quantitative PCR was used to examine the effects of VEGF-E and vIL-10 on equine 
fibroblast gene expression. As the mammalian equivalents of the viral proteins have 
been shown to regulate fibroblast proliferation and migration (Zhao et al., 2013; Zhao 
et al., 2014), a scratch assay was used to examine the effects of VEGF-E and vIL-10 on 
equine fibroblast activity.   
 
3.1.1 Production of the viral proteins 
FLAG-tagged VEGF-E and vIL-10 were purified from supernatant of HEK293-
EBNA cell lines via affinity chromatography and ultracentrifugation. Purified protein 
was resolved on an SDS-PAGE, stained with Coomassie blue. Band densities were 
compared to a standard curve generated using a protein of known concentration (CA). 
Figure 1 shows two bands of 25 and 28 kDa, which are consistent with the molecular 
weight (MW) reported for VEGF-E (Wise et al., 1999). A band was also observed at 20 
kDa that is consistent with the MW of vIL-10 reported previously (Imlach et al., 2002). 





Figure 1. SDS-page quantitation gels of purified VEGF-E and vIL-10 protein. Varying 
amounts of carbonic anhydrase (CA, 100 ng/µL), VEGF-E and vIL-10 were resolved by SDS-
PAGE and stained with Coomassie blue for quantification using densitometry. Size of the 
rainbow marker are indicated. 
 
3.1.2 Generation of an equine cell line 
Three extraction methods and two culture medias were trialed for the extraction 
of skin cells, as described in materials and methods (Table 2). Brick-shaped cells that 
resembled keratinocytes were obtained from the equine skin explants but these cells 
were out competed by fibroblasts.  Similar cells were also obtained following 
collagenase/dispase digestion of the body skin but in this case the cells were unable to 
be passaged more than five times. In contrast, spindle-shaped cells that resembled 
fibroblasts were able to be cultured from body and limb skin from each extraction 
method and using either grown media. 
Table 2. Table showing outcome of cell growth from each extraction method. Crosses 
indicate cells that failed to grow beyond passage 1, ticks indicates methods that isolated pure 
colonies that could be passaged. 






eKGM Keratinocytes ✓ ✓ - up to P5 ✓-  up to P5 
Fibroblasts ✓ ✓ ✓ 
eFGM Keratinocytes ✗ ✗ ✓-  up to P5 
Fibroblasts ✓ ✓ ✓ 
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Two fibroblast-like cell lines, generated from limb and body skin, were 
examined in more detail. To confirm whether the cell lines were indeed fibroblasts, 
these cells were stained with fluorescent antibodies against Vim, which is present in the 
intermediate filaments of fibroblasts (Theoret et al., 2013), and αSMA, which is used to 
differentiate fibroblasts with myofibroblasts (Theoret et al., 2013) (Fig. 2A).  Both the 
limb and body cell lines stained 100% positive for Vim, while approximately 50% of 
cells were also positive for αSMA (Fig. 2A). These findings illustrate that the equine 
cell lines contained a mixture of both fibroblasts and myofibroblasts. 
 
Figure 2. Immunofluorescent and growth analysis of equine cell lines. (A) Images of limb 
and body cells stained with fluorescent antibodies against vimentin (Vim; fibroblasts), α-
smooth muscle actin (α-SMA; myofibroblasts) and a nuclear stain (DAPI). Scale is indicated. 
(B) White light images of limb and body cells taken at 10X magnification. (C) Growth curve of 
cells over a 24 h period. Cells per field of view were counted (n = 3). Values represent the 
mean ± SEM. Scale is indicated. 
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A growth curve was conducted on the fibroblast cell lines originating from limb 
and body skin (Fig. 2B-C). The body fibroblasts doubled in number within the 24 h 
period, while the limb fibroblasts showed very limited proliferation during that time 
frame (Figure 2B-C). From this point, all assays were performed using the faster 
growing equine body fibroblasts. 
To ensure the equine body fibroblasts would be responsive to the viral proteins, 
PCR analysis for the expression of the appropriate VEGF and IL-10 receptors was 
performed. A PCR was conducted on RNA extracted from the cells using primers for 
VEGFR1, VEGFR2 and IL-10Rα and the products were visualised on an agarose gel 
(Fig. 3).  The cell line was shown to express all three of the receptors, showing bands of 
~100 bp which is consistent with the product size expected from these primers (Fig. 3). 
A smaller, fainter band was also observed in the no template control well, which was 
consistent with a dimer forming with the VEGFR-1 primers (Fig. 3).  
These findings demonstrate that a proliferative equine cell line was successfully 
generated that expressed fibroblast markers and the receptors necessary for viral protein 
activity. 
!
Figure 3. PCR analysis of VEGF and IL-10 receptor expression in equine body cells. 
Bands for VEGFR1, VEGFR2, IL-10Rα and control (VEGFR1 primers + no template) are 
indicated. 1 kbp marker is shown.  
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3.1.3 Effects of viral proteins on equine fibroblast gene expression 
Primers were designed for quantitative PCR analysis of genes regulating 
inflammation and fibrosis (equine (e)MIP-2α, eMCP-1, eTNFα, eMMP-1, eCol1α2, 
eαSMA, eVEGF-A, eIL-10, eTGFβ1 and eTGFβ3). Primer pairs were tested using 
cDNA generated from total RNA extracted from the equine body fibroblasts. Primer 
pairs with efficiencies closest to 100% (100 ± 30%) were chosen for the analyses 
(Appendix 1, Supplementary Table 1). The equine fibroblasts were then treated either 
with VEGF-E or vIL-10 alone, or co-treated with polyinosinic:polycytidylic acid 
(polyI:C) to promote an inflammatory response (Hamidi et al., 2014). Total RNA was 
then extracted, cDNA synthesised and gene expression analysed using quantitative 
PCR.  
 
Changes in the expression of genes involved in inflammation (eMIP-2α, eMCP-
1 and eTNFα) following treatment with the viral proteins with or without polyI:C are 
shown in Figure 4. The expression of the inflammatory chemokine eMIP-2α and 
eMCP-1 increased following treatment with PolyI:C (Fig. 4A-B) while very little 
change was observed in the expression of the inflammatory cytokine eTNFα (Fig. 4C). 
Treatment with vIL-10 decreased the expression of eTNFα, in the presence and absence 
of polyI:C (Fig. 4C), but in contrast increased the expression of eMCP-1 in the 
presence of polyI:C (Fig. 4B). No change in expression was observed following VEGF-




Figure 4. Inflammatory gene expression in equine body fibroblasts in response to VEGF-
E or vIL-10. Cells were stimulated with VEGF-E (200 ng/mL), vIL-10 (20 ng/mL) or no 
protein control in media containing 0.1% BSA. Where indicated, polyI:C (50 µg/mL) was 
added concurrently to stimulate an inflammatory response. After 2 h incubation, cells were 
harvested, total RNA extracted and cDNA synthesised. Quantiative PCR analysis was then 
used to detect expression of (A) equine (e)MIP-2α, (B) eMCP-1 and (C) eTNFα. Expression of 
mRNA is relative to that of eGAPDH and to the control unstimulated cells. Values represent 
mean ± SEM (n = 2, mean of duplicates from two replicate experiments). 
 
Changes in the expression of genes involved in fibrosis (eMMP-1, eαSMA and 
eCol1α2) following treatment with the viral proteins are shown in Figure 5. Treatment 
with vIL-10 increased the expression of eMMP-1 (Collagenase-1, Fig. 5A), but had no 
effect on fibroblast expression of eαSMA or eCol1α2 (Fig. 5B-C). No change in 
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harvested,'total'RNA'extracted'and'cDNA'synthesised.'Quantiative'PCR'analysis'was'then'




Changes in the expression of key regulatory genes (eVEGF-A, eIL-10, eTGFβ1 
and eTGFβ3) which control fibroblast proliferation, migration and differentiation 
following treatment with the viral proteins with or without polyI:C are shown in Figure 
6. PolyI:C treatment increased expression of eVEGF-A, eIL-10, eTGFβ1 and eTGFβ3 
compared to the unstimulated control cells (Fig. 6). VEGF-E treatment had no effect on 
the expression of eVEGF-A (Fig. 6A), and increased the expression of eIL-10, although 
a decrease in expression was observed in the presence of polyI:C (Fig. 6B). VEGF-E 
treatment also slightly decreased expression of eTGFβ1 and eTGFβ3, but this decrease 
was not observed after stimulation with polyI:C (Fig. 6C-D).  Viral IL-10 treatment 
increased expression of eVEGF-A and eIL-10 (Fig. 6A-B). Treatment with vIL-10 also 
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decreased expression of eIL-10, eTGFβ1 and eTGFβ3 after stimulation with polyI:C 
(Fig. 6B-D). 
 
These' findings' indicate' that' the' viral' VEGF5E,' to' some' extent,' altered' the' expression' of'
regulatory'genes'in'equine'fibroblasts'but'did'not'impact'the'expression'of'genes'involved'
in' inflammation'or' fibrosis.' The' viral' IL510'dampened' the' expression'of' the' eIL510,' the'
eTGFβ! isoforms' and' eTNFα' by' polyI:C,' and' increased' expression' of' the' degradative'
enzyme,'eMMP51,'in'unstimulated'equine'fibroblasts.'!
 
Figure 6. Regulatory genes in equine body fibroblasts in response to VEGF-E or vIL-10. 
Cells were stimulated with VEGF-E (200 ng/mL), vIL-10 (20 ng/mL) or no protein control in 
media containing 0.1% BSA media. Where indicated, polyI:C (50 µg/mL) was added 
concurrently to stimulate an inflammatory response. After 2 h incubation, cells were harvested, 
total RNA extracted and cDNA synthesised. Quantiative PCR analysis was then used to detect 
expression of (A) eVEGF-A, (B) eIL-10, (C) eTGFβ1 and (D) eTGFβ3. Expression of mRNA 
is relative to that of eGAPDH and to the control unstimulated cells. Values represent mean ± 
SEM (n = 2, mean of duplicates from two replicate experiments). 
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3.1.4 Effects of viral proteins on equine fibroblast migration  
Mammalian VEGFs and IL-10 have both been shown to influence the 
proliferation and migration of human fibroblasts, in a positive and negative manner, 
respectively (Moroguchi et al., 2004; Zhao et al., 2013; Zhao et al., 2014).  In order to 
determine if the viral factors influenced the equine fibroblasts in the same manner, an 
in vitro scratch assay was performed (Rose, 2012).  
Fibroblasts were grown to confluence then a scratch was administered down the 
centre of each well and photos were taken of the cells migrating to close the wound 
(Fig. 7A). The rate of closure over time was calculated and showed that, in the presence 
of 1% FCS, the cells had filled the scratch within 48 h (Fig. 7B-C). In contrast, cells in 
the presence of 0.1% BSA had filled only 20% of the scratch area within 48 h (Fig. 7B-
C). The addition of VEGF-E or vIL-10 to the media containing 0.1% BSA did not, over 
the 48 h period, reduce scratch area from that of the control (Fig. 7B-C). The cells 
treated with vIL-10 did however survive the serum-free conditions better than the cells 
in media containing 0.1% BSA alone (n =5-6, three replicated experiments).  
The results indicate that the vIL-10 and VEGF-E do not significantly impact 






Figure 7. Cellular migration of equine body fibroblasts in response to VEGF-E or vIL-10. 
Confluent fibroblasts were scratched with a 600 µm wide pipette tip then incubated with 
DMEM containing either 1% FCS, 0.1% BSA, or 100 ng VEGF-E or 20 ng vIL-10 with 0.1% 
BSA. (A) White light images taken at 10X magnification. Closure rate following (B) VEGF-E 
or (C) vIL-10 treatment. The closure rate was calculated as a ratio between the area of the 
scratch at each time point compared with the original scratch area. Values represent mean ± 




3.2 In vivo analysis of viral protein activity in equine skin 
wounds 
The second objective of this project was to determine the effects of the viral 
proteins on equine skin wounds. In a trial at Massey University, four thoroughbred 
horses each received four skin wounds on both metacarpal areas (limb) and on both 
thoracic walls (body). Body wounds heal efficiently while limb wounds become 
chronic in nature. At 24, 48 and 72 h post surgery, wounds were randomly administered 
VEGF-E and vIL-10 (10 and 1µg, respectively, in 200 µL PBS) to one limb and one 
body region, while the matching regions received the control treatment (200 µL PBS). 
Biopsies were taken from a single wound in each region at day 2, 7 and 14, and at the 
time of closure.  
 
The viral proteins have both been shown to regulate inflammation, repair and 
remodelling (Wise et al., 2012; Wise et al., 2014), so quantitative PCR was used to 
examine the effects of VEGF-E and vIL-10 on equine skin wound gene expression. As 
the viral proteins have been shown to regulate wound re-epithelialisation (Wise et al., 
2012; Wise et al., 2014), histological analyses were used to examine the effects of 
VEGF-E and vIL-10 on the regenerating epidermis in the equine wounds.  Because the 
viral proteins have been shown to influence wound re-vascularisation (Wise et al., 
2012; Wise et al., 2014), immunofluorescent analyses were used to determine the 
effects of VEGF-E and vIL-10 on blood vessel formation in the equine wounds.  The 
viral proteins have also been shown to influence immune cell trafficking (Wise et al., 
2012; Wise et al., 2014), therefore immunofluorescent analyses were used to evaluate 
the effects of VEGF-E and vIL-10 on antigen-presenting cells within the equine 




3.2.1 Effects of the viral proteins on equine skin wound gene 
expression 
Additional primers were designed for quantitative PCR analysis of genes 
regulating inflammation, repair and remodelling (eFPR2, eIL-10Rα, eCTGF, eSPP-1, 
eCol3α1,  ePDGF-β, eIL-10, eVEGFR-1 and eVEGFR-2). Primer pairs were tested 
using cDNA generated from total RNA extracted from the equine body fibroblasts. 
Primer pairs with efficiencies closest to 100% (100 ± 30%) were chosen for these 
analyses (Appendix 1, Supplementary Table 1). Total RNA was then extracted from 
biopsies taken of the treated and control chronic limb wounds taken at each time point, 
cDNA was synthesised and gene expression analysed using quantitative PCR.  
 
Changes in the expression of pro-inflammatory genes (eMCP-1, eMIP-2α, 
eTNFα and eFPR2) in chronic limb wounds following treatment with the viral proteins 
are shown in Figure 8. Expression of the chemokines, eMCP-1 and eMIP-2α, peaked at 
day 2 and was still above that of unwounded skin at the time of closure (Fig. 8A-B). 
Expression of the cytokine eTNFα showed a slight decrease over time and was below 
that of unwounded skin at the time of closure (Fig. 8C). Expression of the chemotactic 
neutrophil receptor eFPR2 peaked at day 2 and had returned to the level of unwounded 
skin by the time of closure (Fig. 8D). Treatment with the VEGF-E and vIL-10 led to an 
immediate decrease in the expression of eMCP-1, eMIP-2α and eTNFα compared with 
the control wounds at 2 days (Fig. 8A-C, P = 0.01-0.07). No clear differences in the 
expression of the inflammatory genes were observed between control and treated 




Figure 8. Inflammatory gene expression in chronic limb wounds in response to treatment 
with VEGF-E and vIL-10. Limb wounds were generated in horses then were treated at 24, 48 
and 72 h with VEGF-E (10 µg) and vIL-10 (1 µg) in 200 µL PBS (treated), or with PBS alone 
(control). Biopsies of wounds were taken at various timepoints post surgery, total RNA 
extracted and cDNA synthesised. Quantitative PCR analysis was then used to detect expression 
of (A) eMCP-1, (B) eMIP-2α, (C) eTNFα and (D) eFPR2. Expression of mRNA is relative to 
that of eGAPDH and unwounded skin. Values represent mean ± SEM (n = 3-4 horses). An 
unpaired t-test was used to identify significant differences between control and treated horses at 
each time point and P values ≤0.1 are indicated. 
'
Changes in wound expression of the anti-inflammatory genes eIL-10 and eIL-
10Rα following treatment with the viral proteins are shown in Figure 9. Both genes 
showed a steady decrease in expression over time and were well below that of 
unwounded skin by wound closure (Fig. 9). Treatment with the VEGF-E and vIL-10 
led to an immediate decrease in the expression of eIL-10 and a delayed decrease in eIL-
10Rα at 2 and 7 days, respectively, compared with control wounds  (Fig. 9, P = 0.0005-
0.002). No clear differences in the expression of the anti-inflammatory genes were 




Figure 9. Anti-inflammatory gene expression in chronic limb wounds in response to 
treatment with VEGF-E and vIL-10. Limb wounds were generated in horses then were 
treated at 24, 48 and 72 h with VEGF-E (10 µg) and vIL-10 (1 µg) in 200 µL PBS (treated), or 
with PBS alone (control). Biopsies of wounds were taken at various timepoints post surgery, 
total RNA extracted and cDNA synthesised. Quantitative PCR analysis was then used to detect 
expression of (A) eIL-10 and (B) eIL-10Rα. Expression of mRNA is relative to that of 
eGAPDH and unwounded skin. Values represent mean ± SEM (n = 3-4 horses). A paired t-test 
was used to identify significant differences between control and treated horses at each time 
point and P values ≤0.1 are indicated. 
 
Expression of wound repair genes (eVEGF-A, ePDGF-β, eVEGFR-1 and 
eVEGFR-2) following treatment of limb wounds with VEGF-E and vIL-10 is shown in 
Figure 10. Expression of eVEGF-A and ePDGF-β, mitogens for endothelial cells and 
keratinocytes, and pericytes, respectively, decreased over time and were well below 
that of unwounded skin at all time points (Fig. 10A-B). Expression of the VEGF 
receptors, eVEGFR-1 and eVEGFR-2 also decreased initially but eVEGFR-2, unlike 
eVEGFR-1, returned to that of unwounded skin by day 7 (Fig. 10C-D). Treatment with 
the VEGF-E and vIL-10 led to an imediate decrease in the expression of eVEGF-A, at 
day 2 compared with control wounds (Fig. 10A, P = 0.02). The viral protein treatment 
also caused a delayed reduction in the expression of eVEGFR-1 compared to control 
wounds at day 14 (Fig. 10C, P = 0.03). No clear differences in the expression of the 
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Figure 10. Repair gene expression in chronic limb wounds in response to treatment with 
VEGF-E and vIL-10. Limb wounds were generated in horses then were treated at 24, 48 and 
72 h with VEGF-E (10 µg) and vIL-10 (1 µg) in 200 µL PBS (treated), or with PBS alone 
(control).   Biopsies of wounds were taken at various timepoints post surgery, total RNA 
extracted and cDNA synthesised. Quantitative PCR analysis was then used to detect expression 
of (A) eVEGF-A, (B) ePDGFβ, (C) eVEGFR1 and (D) VEFGR2. Expression of mRNA is 
relative to that of eGAPDH and unwounded skin. Values represent mean ± SEM (n = 3-4 
horses). An unpaired t-test was used to identify significant differences between control and 
treated horses at each time point and P values ≤0.1 are indicated. 
 
Expression levels of regulatory genes involved in wound fibrosis (eCTGF, 
eSPP-1, eTGFβ1 and eTGFβ3) following treatment with VEGF-E and vIL-10 are 
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shown in Figure 11. Expression of the fibroblast mitogen eCTGF initially decreased at 
2 days and began to increase back to the level of unwounded skin by the time of closure 
(Fig. 11A). Expression of the immune-stimulatory eSPP-1/Osteopontin also decreased 
at 2 days and remained below that of unwounded skin (Fig. 11B). Expression of the 
fibrosis regulators eTGFβ1 and eTGFβ3 initially decreased at 2 days, but increased to 
above that of unwounded skin by day 14 (Fig. 11C-D). Treatment with the VEGF-E 
and vIL-10 led to decreases in the expression of eSPP-1/osteopontin, eCTGF and the 
TGFβ isoforms at days 2, 7 and 14, respectively, compared with control wounds  (Fig. 
11, P = 0.001-0.07). No clear differences in the expression of the fibrosis genes were 








Figure 11. Fibrosis regulatory gene expression in chronic limb wounds in response to 
treatment with VEGF-E and vIL-10. Limb wounds were generated in horses then were 
treated at 24, 48 and 72 h with VEGF-E (10 µg) and vIL-10 (1 µg) in 200 µL PBS (treated), or 
with PBS alone (control). Biopsies of wounds were taken at various timepoints post surgery, 
total RNA extracted and cDNA synthesised. Quantitative PCR analysis was then used to detect 
expression of (A) eCTGF, (B) eSPP-1, (C) eTGFβ1 and (D) eTGFβ3. Expression of mRNA is 
relative to that of eGAPDH and unwounded skin. Values represent mean ± SEM (n = 3-4 
horses). An unpaired t-test was used to identify significant differences between control and 
treated horses at each time point and P values ≤0.1 are indicated.!' !
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Extracellular matrix gene expression (eCol1α2, eCol3α1, eαSMA and eMMP-1) 
following treatment of limb wounds with VEGF-E and vIL-10 is shown in Figure 12. 
Expression of collagen types eCol1α2 and eCol3α1 increased over time and were at 
their highest level at the time of wound closure (Fig. 12A-B). Expression of the 
contractile protein eαSMA increased from day 2 to 14 and was closer to that of 
unwounded skin by the time of wound closure (Fig. 12C). Expression of the digestive 
enzyme eMMP-1/collagenase-1 was substantially increased between 2-14 days and was 
restored to that of unwounded skin by wound closure (Fig. 12D). Treatment with the 
VEGF-E and vIL-10 led to a decrease in the expression of eCol3α1, at day 7 compared 
with control wounds (Fig. 12B, P = 0.02). The viral protein treatment also altered the 
expression of eαSMA compared to control wounds with a decrease at day 7 (Fig. 11C, 
P = 0.06) and an increase at the time of wound closure (Fig. 12C, P = 0.01). No clear 
differences in the expression of the extracellular matrix genes were observed between 
control and treated wounds at any other time point (Fig. 12). 
 
These results indicate that treatment with the VEGF-E and vIL-10 had a 
transient influence on the expression of key regulators of inflammation, repair and 






Figure 12. Extracellular matrix gene expression in chronic limb wounds in response to 
treatment with VEGF-E and vIL-10. Limb wounds were generated in horses then were 
treated at 24, 48 and 72 h with VEGF-E (10 µg) and vIL-10 (1 µg) in 200 µL PBS (treated), or 
with PBS alone (control).  Biopsies of wounds were taken at various timepoints post surgery, 
total RNA extracted and cDNA synthesised. Quantitative PCR analysis was then used to detect 
expression of (A) eCol1α2, (B) eCol3α1, (C) eαSMA and (D) eMMP-1. Expression of mRNA 
is relative to that of eGAPDH and unwounded skin. Values represent mean ± SEM (n = 3-4 
horses). An unpaired t-test was used to identify significant differences between control and 





3.2.2 Effects of the viral proteins on epidermal repair in equine skin 
wounds 
In order to assess the effects of the viral treatment on the regenerating 
epidermis, zinc-fixed paraffin-embedded sections of biopsies taken from the limb and 
body wounds at each time point were stained with Martius Scarlet Blue (MSB). Figure 
13 shows representative images of sections of control and treated chronic limb wounds 
taken at day 7, 14 and after final wound closure. Equivalent images of MSB-stained 
sections of body wounds are shown in Appendix 1, Supplementary Figure 1. After 7 
days, a new epidermis was projecting from the wound edge in both body and chronic 
limb wounds and there was an increase in epidermal length observed in treated wounds 
when compared to controls (Fig. 13A, Sup. Fig. 1A). After 14 days, the new epidermis 
had thickened at the wound edge in the chronic limb wounds while this was not really 
observed in the body wounds (Fig. 13B, Sup. Fig. 1B).  No difference in epidermal 
thickness was observed between treated and control wounds at this time (Fig. 13B, Sup. 
Fig. 1B). At the time of wound closure the epidermis had in general covered the entire 
wound bed but in chronic limb wounds there was an extensive network of epidermal 
projections (rete ridges) extending into the new dermis (Fig. 13C, Sup. Fig. 1C). No 
obvious difference in rete ridge formation was observed between treated and control 




Figure 13. Epidermal repair in chronic limb wounds in response to treatment with 
VEGF-E and vIL-10. Images of MSB-stained sections from treated and control chronic limb 
wounds harvested at (A) 7 days, (B) 14 days and (C) at final wound closure. Fibrin is stained 
red and collagen stained blue. ImageJ software was used to measure the length (contoured 
yellow line illustrated in (A)), thickness (five yellow lines; thickness calculated as mean length 
of five lines illustrated in (B)) and rete ridge formation (green arrows; calculated as cumulative 
length illustrated in (C)) in the newly regenerating epidermis. Scale is indicated.  
 
Image J was then used to analyse these physical changes observed in the 
regenerating epidermis of body and chronic limb wounds between those treated with 
VEGF-E and vIL-10 or the control. The length and thickness of the regenerating 
!
! 46!
epidermis was measured for each section as well as the cumulative length of all the rete 
ridges (Fig. 14). The epidermal length was similar in chronic and body wounds at day 7 
and 14 but by wound closure the epidermal projections had substantially increased the 
overall length of the epidermis in the chronic wounds (Fig. 14A-B). Treatment with 
VEGF-E and vIL-10 had increased the length of the new epidermis after 7 days in both 
chronic limb and acute body wounds (Figure 14A-B, P = 0.07-0.09), but no differences 
were observed between the treated and control wounds after that point.  
 
The epidermal thickness increased dramatically in chronic wounds at day 14 
until wound closure but remained constant in the body wounds (Fig. 14C-D). Treatment 
with VEGF-E and vIL-10 increased the thickness of the new epidermis in body wounds 
after 7 days (Figure 14D, P = 0.04), but no differences were observed between the 
treated and control limb wounds (Fig. 14C).  
 
Rete ridge formation also increased dramatically in chronic wounds from day 7 
until wound closure but remained constant in the body wounds (Fig. 14E-F). Treatment 
with VEGF-E and vIL-10 however had no measurable effect on the cumulative length 
of the rete ridges compared to control wounds (Figure 14E-F).  
 
These results indicate that treatment with the VEGF-E and vIL-10 induced a 




Figure 14. Quantification of epidermal repair in equine wounds in response to treatment 
with VEGF-E and vIL-10. ImageJ software was used to measure (A-B) epidermal length, (C-
D) epidermal thickness and (E-F) rete ridge formation in MSB-stained sections from chronic 
(A, C, E) and body (B, D, F) equine wounds. Thickness is calculated as mean of five 
measurements and rete ridge formation is calculated as the cumulative length of all rete ridges. 
Values represent mean ± SEM (n = 3-4). An unpaired t-test was used to identify significant 




3.2.3 Effects of the viral proteins on re-vascularisation of equine skin 
wounds 
In order to assess the effects of the viral treatment on the production of new 
blood vessels, zinc-fixed paraffin-embedded sections of biopsies taken from the limb 
and body wounds at each timepoint were stained with fluorescent antibodies against 
vWF, which stains endothelial cells and factor VIII released by permeable vessels and 
αSMA which is found in pericytes lining mature blood vessels and in contractile 
myofibroblasts. Figure 15 shows representative images of sections of control and 
treated chronic limb wounds taken after 7 and 14 days. Equivalent images of 
vWF/SMA  stained sections of body wounds are shown in Appendix 1, Supplementary 
Figure 2. After 7 days, a large amount of vWF staining was observed at the new 
granulation tissue of both chronic and body wounds and a further increase was 
observed after 14 days (Fig. 15, Sup. Fig. 2). At 7 days, vWF staining appeared to be 
greater in treated wounds than in both the chronic and body control wounds, (Fig. 15, 
Sup. Fig. 2). A large amount of αSMA staining was also observed in the wounds, which 
increased between 7 and 14 days (Fig. 15, Sup. Fig. 2), although the levels were more 
variable in the limb wounds. Although an increase in αSMA staining was observed in 
treated limb wounds at day 7, there appeared to be less staining in the treated limb and 
body wounds than the controls by day 14 (Fig. 15, Sup. Fig. 2).   
 
Closer examination of the stained sections showed that, at day 7 and 14, mature 
blood vessels, in which vWF+ve endothelial cells were lined by αSMA +ve pericytes (Fig. 
16A), were present in the granulation tissue of both control and treated wounds. At day 
7, however, there was a large amount of vWF staining that was not associated with 
nuclei (Fig. 16B), which indicates factor VIII release from leaky vessels. This was 
particularly evident in the treated limb sections. At day 7 and day 14, αSMA +ve 
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myofibroblasts, that were not associated with vWF+ve endothelial cells (Fig. 16C), were 
present in the granulation tissue of both control and treated wounds. These cells were 
most evident in the control limb sections and appeared to be reduced in number or 
intensity in body and treated wounds. 
 
 
Figure 15. Re-vascularisation in chronic limb wounds in response to treatment with 
VEGF-E and vIL-10. Images of sections from treated and control chronic limb wounds from 
(A) 7 days and (B) 14 days, stained with antibodies against vWF (marker of endothelial cells 
and factor VIII), αSMA (marker of pericytes and myofibroblasts) and DAPI (nuclear stain). 
ImageJ software was used to determine the percentage of the granulation tissue area stained 





Figure 16. Specific staining of features in equine wounds shown by staining with vWF and 
αSMA. Images showing (A) αSMA+/vWF+ mature blood vessels in a control body wound at 7 
days, (B) αSMA-/vWF+ staining of Factor VIII indicating edema in a control chronic wound at 
7 days and (C) αSMA+/vWF- myofibroblasts in a control chronic wound at 14 days. Individual 
and merged images are shown. Scale is indicated. 
 
Image J was then used to analyse the gross changes in vWF and αSMA staining 
in the granulation tissue of body and chronic limb wounds between those treated with 
VEGF-E and vIL-10 and the controls. The percentage area of granulation tissue stained 
with vWF increased from day 7 to day 14 in both body and limb wounds (Fig. 17A-B). 
There was a trend towards increased staining of vWF in the treated wounds compared 
to the control wounds at 7 days (Fig. 17A-B), but no differences were observed after 14 
days. The percentage area of αSMA staining also increased from day 7 to day 14 in 
both body and limb wounds (Fig. 17C-D). There was a slight increase in staining of 
αSMA in the treated limb wounds compared to the control wounds at 7 days, but by 14 
!
! 51!
days there was a slight reduction in the treated body and limb wounds compared with 
the matched controls. 
These results indicate that treatment with the VEGF-E and vIL-10 may have 
influenced blood vessel and myofibroblast formation in the equine wounds but more 




Figure 17. Quantification of re-vascularisation in equine wounds in response to treatment 
with VEGF-E and vIL-10. Image J software was used to measure the percentage of 
granulation tissue area stained with (A-B) vWF or (C-D) αSMA in sections from (A, C) chronic 
and (B, D) body  wounds. Values represent mean ± SEM (n = 3-4). An unpaired t-test was used 
to identify significant differences between control and treated horses at each time point and no 




3.2.4 Effects of the viral proteins on innate immune cell trafficking in 
equine skin wounds 
In order to assess the effects of the viral treatment on the immune cell content, 
zinc-fixed paraffin-embedded sections of biopsies taken from the limb and body 
wounds at day 7 were stained with fluorescent antibodies against major 
histocompatibility complex class II  (MHC-II), which stains dendritic cells, monocytes 
and macrophages. Figure 18 shows a representative image of a section from control and 
treated chronic limb wounds. Equivalent images of MHC-II stained sections of body 
wounds are shown in Appendix 1, Supplementary Figure 4. At 7 days, a small amount 
of MHC-II staining was observed at the edge of the granulation tissue and scattered 
throughout the adjacent tissue (Fig. 18A-B, Sup. Fig. 4A-B). Closer examination 
showed the staining was specific for nucleated cells (Fig. 18C). A decrease in the 
number of cells stained with MHC-II was also evident in the  chronic limb wounds 
treated with the VEGF-E and vIL-10 when compared with control wounds (Fig. 18A-
B). 
Image J was then used to analyse the overall change in MHC-II staining in the 
wound sections from body and chronic limb wounds between those treated with VEGF-
E and vIL-10 and the controls. The percentage area of tissue stained with MHC-II at 
day 7 was variable but equivalent in the body and limb wounds (Fig. 19A-B). There 
was however a trend towards a decrease in MHC-II staining in the treated limb and 
body wounds compared to their controls (Fig. 19A-B, not significant and P = 0.1 
respectively).  
These results indicate that treatment with the VEGF-E and vIL-10 may have 
reduced the recruitment of innate immune cells into the equine wounds but more 




Figure 18. Immune cells in chronic limb wounds in response to treatment with VEGF-E 
and vIL-10. Images of sections from (A) control and (B) treated chronic wounds from 7 days 
stained with an antibody against MHC-II and DAPI (nuclear stain). (C) Images showing MHC-














Figure 19. Quantification of innate immune cell content in equine wounds in response to 
treatment with VEGF-E and vIL-10. Image J software was used to measure the percentage of 
the section from (A) chronic and (B) body wounds stained with MHC-II. Values represent 
mean ± SEM (n = 3-4). Values represent mean ± SEM (n = 3). A paired t-test was used to 
identify significant differences between control and treated horses at each time point and P 





VEGF-E and vIL-10 have previously been shown to improve skin repair by 
improving wound re-epithelisation, vascularisation and by limiting inflammation and 
fibrosis. This project aimed to determine the effect of the above-mentioned proteins in 
equine tissue. There were two objectives to this study; the first to determine if the viral 
proteins are effective on equine cells using an in vitro equine cell line, and second to 
determine if the proteins improved healing in horses in an in vivo trial of chronic equine 
wounds.  
4.1 VEGF-E in equine systems 
VEGF-E is a vascular endothelial growth factor, and has been previously 
reported to increase vascularisation and epidermal regeneration in murine wounds and 
in ovine skin (Savory et al., 2000; Wise et al., 2007; Wise et al., 2012; Wise et al., 
2003). The cellular homolog, VEGF-A, has also been shown to increase human 
fibroblast proliferation (Zhao et al., 2013). VEGF-E has been shown to increase genes 
involved in inflammation in murine and human cells, as well as induce changes in 
expression of VEGF-A and the VEGF receptors (unpublished). These changes in 
VEGF expression are relative to the dosage of the VEGF-E; low levels of VEGF-E will 
upregulate the expression of cellular VEGF and its receptors, while too much VEGF-E 
will cause a negative-feedback loop resulting in a down regulation of cellular VEGF. 
Orf virus primarily infects sheep, and the ovine receptor for VEGF-E, VEGFR2, shares 
84% amino acid homology with the murine equivalent. Equine VEGFR2 shares an 
even closer 94% homology to the ovine receptor, indicating that VEGF-E will actively 
bind the equine receptor. 
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An equine fibroblast cell line expressing eVEGFR2 was used to determine the 
effects of VEGF-E on proliferation, migration, and gene expression. The results of the 
scratch assay showed no changes in proliferation or migration in response to VEGF-E. 
The protein altered the expression of eIL-10 in the fibroblasts, but had no other effects 
on gene expression. These results indicate that VEGF-E is having virtually no effect on 
the fibroblasts. One potential hypothesis for this result is that VEGF-E is not a mitogen 
for equine fibroblasts. Another hypothesis could be that the effects of VEGFs in equine 
fibroblasts are not mediated through VEGFR2, but rather through either VEGFR1 or 
VEGFR3. This would suggest that VEGF-E may have the ability to work in other 
equine cells to promote proliferation. As VEGF-E has been previously shown to 
activate murine keratinocytes, the equine equivalent of these cells would be a more 
suitable cell line to use to observe the bioactivity of the viral proteins. Equine 
endothelial cells may also exhibit responses to VEGF-E.  
Chronic wounds were developed in thoroughbred horses and treated with a 
combination of vIL-10 and VEGF-E, to determine the effectiveness of the viral proteins 
in improving wound repair. Skin samples were analysed for changes in histology and 
gene expression. An immediate increase in Factor VIII staining was seen for the treated 
samples, indicating an increase in edema. This was accompanied by swelling around 
the wound edge, as illustrated by images taken of the treated wound sites (Appendix 1, 
Supplementary Figure 3). These findings indicate VEGF-E treatment has induced an 
increase in vascular permeability. Gene expression analyses of chronic wounds showed 
that VEGF-A was down regulated in response to the proteins. This indicates that 
perhaps the concentration of VEGF-E administered was too high, resulting in a 
negative regulation of its cellular counterpart.  
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Skin samples were also stained against α-SMA to identify pericytes surrounding 
blood vessels. This staining was greater in treated samples at later time points, 
indicating that there are more mature blood vessels in response to the treatment. 
However, the integrity of these vessels is not known. This finding is concurrent with 
other publications which indicate that equine limb wound beds are highly vascularised, 
but vessels are occluded and so the wound lacks adequate levels of oxygen (Dubuc et 
al., 2006; Lepault et al., 2005). This project did not investigate the integrity of the blood 
vessels, and so further analysis would be required to determine if treatment with the 
viral proteins had any impact on their integrity. Histological analysis can be performed 
using transmission electron microscopy to examine the cross-section of blood vessels 
and measure the size of endothelial cells in order to determine if the lumen of the vessel 
is being occluded by oversized endothelial cells, as shown in previous studies.  
VEGF-E has been shown to increase epidermal regeneration, and the results 
from the in vivo portion of this study concurred with these findings. However, gross 
analysis of the horse wounds found that there were no changes in overall wound closure 
(unpublished), and this suggests the epidermal regeneration observed in this study was 
only a transient response. This could indicate that the VEGF-E treatment is having an 
effect on the skin, but only for a short period of time. The treatment regime needs to 
extend over a longer period of time if it is to promote wound closure.  
VEGFR2 expression significantly decreased in limb skin in the first 48 hours 
after wounding, during which time the treatment was applied. This could result in poor 
VEGF-E signalling, limiting the effects seen in response to the protein. VEGF-E 
dosage also requires further optimisation, as the immediate response in edema and 
swelling and the decrease in VEGF-A expression indicate that while the protein appears 
!
! 58!
to exert some effect on the skin, the concentration of VEGF-E in this treatment may 
have been too high. 
4.2 Viral IL-10 in equine systems 
Viral IL-10 has been shown to reduce inflammation and fibrosis in murine 
wounds to reduce scarring and enhance wound repair (Wise et al., 2014). Cellular IL-10 
has also been shown to limit fibroblast migration and regulate collagen production 
through the induction of MMP-1 (Moroguchi et al., 2004; Yamamoto et al., 2001). 
Treatment with vIL-10 has previously been shown to reduce the expression of genes 
involved in inflammation and fibrosis, as well as limit fibroblast proliferation and 
prevent infiltration of immune cells (Wise et al., 2014).  
The ovine receptor for IL-10, IL-10Rα, shares 53% amino acid homology with 
the murine equivalent. Equine IL-10Rα shares an even closer 65% homology to the 
ovine receptor, indicating that IL-10 will actively bind the equine receptor. 
Equine fibroblasts showed no change in proliferation or migration when 
exposed to vIL-10. There was however an increase in the production of collagenase-1 
and a reduction in the expression of anti-inflammatory genes. The changes in equine 
fibroblast gene expression in response to polyI:C showed varying effects, indicating 
that further optimisation of polyI:C concentration is needed. The treatment of equine 
fibroblasts with vIL-10 indicated that the protein may be having a small effect, but 
further optimisation of dosage and timing in the assays is required. 
The treatment of chronic wounds in horses consisted of a combination of 
VEGF-E and vIL-10. It was expected that vIL-10 would down regulate the genes 
involved in inflammation and fibrosis and prevent inflammatory cell infiltration into 
the wound. The results of wound gene expression analyses showed a temporary 
reduction in inflammatory and fibrotic genes in response to the protein treatment, as 
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well as changes in anti-inflammatory genes. The reduction in IL-10 expression 
indicates a negative feedback loop preventing further production of IL-10. The receptor 
for IL-10 was upregulated in treated samples, indicating that the vIL-10 is promoting an 
increase in cell signalling. Viral IL-10 has also been shown to reduce fibrosis and 
prevent scarring (Wise et al., 2014). TGFβ1 is a cytokine that stimulates fibroblasts to 
produce collagen. This study showed that viral protein treatment transiently reduced the 
expression of TGFβ1 and Col3α1, which may reduce the amount of collagen produced 
and could limit scarring.  
Treatment of murine wounds with vIL-10 was shown to reduce macrophage 
infiltration (Wise et al., 2014). Immunohistochemical staining of wound tissue showed 
a reduction in MHC-II+ cells in treated skin after 7 days. This correlates with the 
reduction of inflammatory gene expression, indicating that vIL-10 is preventing the 
infiltration of innate immune cells such as monocytes and dendritic cells by reducing 
the production of inflammatory cytokines and chemokines.  
Treatment of murine wounds with vIL-10 has previously been shown to reduce 
myofibroblast differentiation while increasing the association of pericytes with 
endothelial cells (Wise et al., 2014). Immunohistochemical staining against αSMA and 
vWF indicated an increase in the amount of blood vessels in treated samples. While the 
increase in the number of blood vessels is likely due to the effects of VEGF-E, the 
greater αSMA staining around the blood vessels after 14 days indicates an increase in 
pericyte coverage, which results in more stable vessels (von Tell et al., 2006). The 
overall reduction in αSMA staining in treated wounds may also indicate a reduction in 
myofibroblast differentiation. 
The effects of the vIL-10 protein appeared to be transient and there were no 
long-term changes in wound closure or scarring (unpublished). Expression of the IL-
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10Rα receptor decreased over time, and the low expression of this receptor may result 
in a reduction in responsiveness, and therefore less long-term effectiveness. The 
treatment was only administered within the first 72 hours after wounding, and led to 
increased expression of the IL-10 receptor; hence if the timing of the treatments were 
extended to a longer period of time, there may be more improved long-term wound 
resolution. 
4.3 Limitations of VEGF-E and vIL-10 as an equine 
therapeutic 
In summary, no clear effects of the viral proteins were observed using equine 
fibroblasts, and the effects seen in equine skin appeared to be transient and did not 
result in an improved wound closure rate. To obtain therapeutic benefits for chronic 
equine wounds the treatment regime would need further optimisation to establish a 
more effective concentration and dosing regime. 
Changes were seen in the epidermal coverage of the wound in the 14-day 
period. This indicates that VEGF-E is having an effect on wound closure. However, 
this treatment was administered subcutaneously, and this could mean that the treatment 
is not having the desired chemotactic effect on the upper epidermal layer as it is 
administered too far from the site. For this reason, a topical application of VEGF-E 
directly onto the wound may exhibit greater epidermal closure over the wound healing 
period. 
Osteopontin is expressed on inflammatory cells such as macrophages, and the 
expression of this gene was reduced in the wounded equine skin, indicating that there is 
a lack of macrophages in the wound during repair and resolution. Macrophages release 
cytokines such as VEGF which promotes angiogenesis and TGFβ1 and PDGF to 
promote vessel stabilisation (Wynn and Barron, 2010). Treatment of a reduced dose of 
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VEGF-E, or even equine VEGF-A early in the wounding process would result in a low 
level of sustained inflammation to allow the infiltration of innate immune cells, 
including macrophages. This would stimulate a small inflammatory response that 
would promote blood vessel formation. Viral or equine IL-10 introduced later in the 
treatment could then act to dampen these responses to prevent the extended 
inflammatory response and the development of excessive fibrosis, thus allowing the 
wound to close effectively while reducing scar formation.  
VEGF-E increased the production of blood vessels, but this was accompanied 
with an increase in Factor VIII staining, indicating that the vessels were permeable. 
PDGF or angiopoietin-1 can increase the maturation and integrity of blood vessels by 
recruiting pericytes to the vessels (Bergers and Song, 2005; Heldin and Westermark, 
1999; Moss, 2013). The expression of PDGFβ1 was significantly reduced in wounded 
skin. PDGFβ or Ang1 could be added early in the treatment regime to increase levels 
and thereby help to stabilise new blood vessels and improve functionality. 
Alternatively, the anti-angiogenic molecules SPARC, THBS2 or PEPF, which are also 
under expressed in equine limb wounds could be concurrently administered with 
VEGF-E to improve vessel function (Theoret and Wilmink, 2013). 
4.4 Concluding remarks 
The aim of this preliminary study was to determine if vIL-10 and VEGF-E 
would act on equine cells. An equine fibroblast cell line was generated, and the proteins 
had little effect on migration and minor effects on the expression of inflammatory and 
fibrotic genes. The proteins did have an effect in chronic limb wounds, altering 
expression of inflammatory and fibrotic genes and increasing wound re-vascularisation 
and epidermal regeneration, while limiting innate immune cell recruitment. However, 
these results were transient and there was no overall change in the rate of wound 
!
! 62!
closure. Therefore, further optimisation is required if these proteins were to be pursued 
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Supplementary Table 1. Primers used in this study. Table outlining primer names, accession numbers, sequences, product sizes and efficiencies. 
Gene name Accession no Reference Primer name Primer sequence Size % efficiencies 
eGAPDH NM_001163856.1 Taylor et al 2009 eGAPDH F1 GCATCGTGGAGGGACTCA 84 105.35 
   eGAPDH R1 GCCACATCTTCCCAGAGG   
eTNF-α NM_001081819.1 Sanchez-Matamoros et al 2013 eTNF-a F2 TTACCGAATGCCTTCCAGTC 85 114.35 
   eTNF-a R2 GGGCTACAGGCTTGTCACTT   
eVEGF-A NM_001081821.1 Desnene et al 2012 F primer eVEGF-A F1 CAACGACGAGGGCCTAGAGT 94 134.62 
  changes to R primer eVEGF-A R1 TCCTATGTGTTGGCTTTGGTGAGGT   
eCol1α2 XM_001492939.2 Taylor et al 2009 eCol1a2 F1 GCACATGCCGTGACTTGAGA 87 99.66 
   eCol1a2 R1 CATCCATAGTGCATCCTTGATTAGG   
eCol3α1 XM_001917620.3 Taylor et al 2009 eCol3a1 F1 ACGCAAGGCCGTGAGACTA 63 105.25 
   eCol3a1 R1 TGATCAGGACCACCAACATCA   
eMCP-1 NM_001081931.2 seq builder eMCP-1 F1 GACCATATTGGCCAAGGAGATCTGTG 98 87.72 
   eMCP-1 R1 AAGGCTTTGGAGTTTGGGCTTTC   
eMIP-2α NM_001143955.1 seq builder eMIP-2a F1 ATAGCCACTCTCAAGAATGGACAGGA 102 107.71 
   eMIP-2a R1 TCAGTCGGAGCTGCCCTTGTTTA   
eαSMA XM_001503035.4 seq builder eaSMA F2 TCCGGGGGCACCACCAT 135 93.43 
   eaSMA R2 GGAGCCGCCAATCCAGACAG   
eTGFβ1 NM_001081849.1 seq builder eTGFb1 F1 GCAGAGCTGCGCCTCCTAAGG 96 92.71 
   eTGFb1 R1 GTTACTGAGGTAGCGCCAGGAATTATTG   
!
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eTGFβ3 XM_001492687.4 seq builder eTGFb3 F1 CCATAAGTTCGACATGATCCAGGGC 103 90.94 
   eTGFb3 R1 CACTGAGGACACGTTGAAGCGG   
eIL-10 NM_001082490.1 seq builder eIL-10 F3 CAAGGCAGTGGAGCAGGTGAAGA 118 117.12 
   eIl-10 R3 CTTCGTTGTCATATAGGCTTCTATGTAGTTGAT   
eCTGF XM_001503316.3 seq builder eCTGF F1 GCCTTGCGAAGCTGACCTGG 88 95.63 
   eCTGF R1 CTCGAACTTGACAGGCTTGGAGATTT   
eVEGF-R1 XM_003363176.2 seq builder eVEGF-R1 F3 CTTTCACCAGATGCCCCTTCCAT 112 123.07 
   eVEGF-R1 R3 AGGCCTTGGGTTTGCTCTCAGTC   
eSPP-1 XM_001496152.2 seq builder eSPP-1 F3 CCGTGATTTGCTTATGCCTCTTAGG 125 106.76 
   eSPP-1 R3 CTTGAGCCATATGCTTACAGCATCTGA   
eVEGF-R2 XM_00191694.3 seq builder eVEGF-R2 F2 CAGTTGGGCTAAATGAGAGTTCCTTGTG 114 100.92 
   eVEGF-R2 R2 GCCAGAGCTCATCATTTCCTTCCT   
eFPR2 XM_005596470.1 seq builder eFPR2 F2 GAAGAGGAAGATAACCGTCACTGTGTTG 113 85.65 
   eFPR2 R2 TGGCAGCAATGAGGCCATAGC   
eMMP-1 NM_001081847.2 seq builder eMMP-1 F3 CAAATGGACTTCAAGCTGCTTATGAGG 106 87.72 
   eMMP-1 R3 TATCCGTAGAGCACATCCTGCCC   
PDGFβ XM_005606646.1 seq builder ePDGFβ F2 CGAGCCGGACAGCTTATCCC 107 91.64 
   ePDGFβ R2 AGATCTCGAACACCTCGGTGCG   
IL-10Rα XM_001917543.2 seq builder eIL-10Rα F2 GGCGGTCTCCTGGGCACAT 87 91.64 





Supplementary Figure 1. Epidermal repair in body wounds in response to treatment with 
VEGF-E and vIL-10. Images of MSB-stained sections from treated and control body wounds 
harvested at (A) 7 days, (B) 14 days and (C) at final wound closure. Fibrin is stained red and 
collagen stained blue. ImageJ software was used to measure the length (contoured yellow line 
illustrated in (A)) and thickness (five yellow lines; thickness calculated as mean length of five 





Supplementary Figure 2.!Re-vascularisation in chronic limb wounds in response to 
treatment with VEGF-E and vIL-10. Images of sections from treated and control chronic 
limb wounds from (A) 7 days and (B) 14 days, stained with antibodies against vWF (marker of 
endothelial cells and factor VIII), αSMA (marker of pericytes and myofibroblasts) and DAPI 
(nuclear stain). ImageJ software was used to determine the percentage of the granulation tissue 






Supplementary Figure 3. Skin reaction to PBS or protein treatment. Images showing a 
flare response in equine skin wounds treated with (B) proteins (vIL-10 and VEGF-E), 





Supplementary Figure 4. Immune cells in body wounds in response to treatment with 
VEGF-E and vIL-10. Images of sections from (A) control and (B) treated body wounds from 
7 days stained with an antibody against MHC-II and DAPI (nuclear stain). 
